Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?

Mastorino, Luca; Dapavo, Paolo; Avallone, Gianluca; Merli, Martina; Cariti, Caterina; Rubatto, Marco; Pala, Valentina; Quaglino, Pietro; Ribero, Simone

doi:10.1080/09546634.2021.1970706

Cited by 26 publications

(34 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We included patients with a recent history of malignancy, with a median interval between cancer diagnosis and initiation of secukinumab treatment of 3.5 years. The tumor types as well as the early stage of the neoplastic disease were similar to previous case series [13][14][15][16]. We observed an absence of recurrence and progression over a mean of 56 ± 31.7 weeks of secukinumab treatment.…”

Section: Discussionsupporting

confidence: 88%

“…We observed an absence of recurrence and progression over a mean of 56 ± 31.7 weeks of secukinumab treatment. The rate of new diagnoses was comparable to the published data [ 13 – 16 ]. Three patients developed a second malignancy during treatment, in two cases unrelated to the previous neoplasm.…”

Section: Discussionsupporting

confidence: 87%

“…To date, few reports have described real-life experiences of the use of biological drugs in psoriatic patients with a history of malignancy [13][14][15][16]. All of these were case series limited in sample size, with a total of 75 cases described, and presented overall data on several classes of biologics, not focusing on a specific drug.…”

Section: Discussionmentioning

confidence: 99%

“…Progression was observed in two patients with advanced disease [ 14 ]. Finally, Mastorino et al [ 16 ] described 37 psoriatic patients, 21 of whom were treated with secukinumab for a mean of 33.1 months after tumor diagnosis. No recurrence was observed, and only one patient with advanced endometrial cancer progressed during secukinumab therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Psoriasis patients with a personal history of malignancy are a special population often excluded from clinical trials investigating biologics. In addition, real-life experiences describing the treatment of such patients with biologics are limited to a few case series [13][14][15][16]. Accordingly, the purpose of our study was to report a multicenter real-life experience of secukinumab treatment in adult patients with moderate-to-severe psoriasis and a history of cancer.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study

Pellegrini

Esposito

Rossi

et al. 2022

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

Introduction: There is limited evidence to guide clinicians on the treatment of psoriasis with biologics in patients with a history of malignancy who are often excluded from clinical trials investigating biologics. The aim of this work is to report a multicenter real-life experience of secukinumab treatment in patients with psoriasis and a personal history of cancer. Methods: This retrospective observational study included adult patients with moderate-tosevere plaque psoriasis treated with secukinumab for at least 24 weeks and a previous diagnosis of cancer at 15 Italian referral centers. The primary endpoint of the study was tumor

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study

Pellegrini

Esposito

Rossi

et al. 2022

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

show abstract

Can we treat anti‐PD1 induced psoriasis in patients with active cancer with biologic therapy? Report of three cases

Jiménez

Ibarguren

Butrón

et al. 2023

JEADV Clinical Practice

View full text Add to dashboard Cite

Predicting discontinuation of biologic therapy caused by adverse events in psoriasis patients—A Danish nationwide cohort study

Nielsen,

Petersen,

Maul

et al. 2023

JEADV Clinical Practice

View full text Add to dashboard Cite

BackgroundSome patients treated with biologic therapy for psoriasis experience adverse events causing treatment discontinuation.ObjectivesTo identify predictors of adverse events resulting in discontinuation of biologics for psoriasis.MethodsThis cohort study involved data from the Danish nationwide registry DERMBIO. A classification algorithm based on gradient‐boosted decision trees combined with a mixed‐effects model was applied to data on various drugs to predict treatment discontinuation caused by adverse events and to identify important predictors.ResultsThis study comprised 4876 treatment series, including 3078 (63.1%) that were discontinued. With adverse events causing 19.6% of these, it was the second most frequent reason for discontinuation following ineffectiveness. The proportion of treatments discontinued due to adverse events was 20.0% [16.7%, 23.9%; 95% confidence interval (CI)] among patients that had discontinued their previous treatment series due to adverse events, and 11.6% [10.3%, 13.1%; 95% CI] among treatment series where the previous treatment was discontinued due to other reasons (p < 0.001).ConclusionsThe proportion of treatment series discontinued due to adverse events among patients who had discontinued their previous treatment due to adverse events was 72.4% larger compared to those who discontinued their previous treatment for other reasons.

show abstract

Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?

Cited by 26 publications

References 19 publications

Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study

Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study

Can we treat anti‐PD1 induced psoriasis in patients with active cancer with biologic therapy? Report of three cases

Predicting discontinuation of biologic therapy caused by adverse events in psoriasis patients—A Danish nationwide cohort study

Contact Info

Product

Resources

About